<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02273895</url>
  </required_header>
  <id_info>
    <org_study_id>MC-CT-001</org_study_id>
    <nct_id>NCT02273895</nct_id>
  </id_info>
  <brief_title>The Use of EEG in Alzheimer's Disease, With and Without Scopolamine - A Pilot Study</brief_title>
  <official_title>Development of a Diagnostic Tool for Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mentis Cura</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Landspitali University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mentis Cura</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the electroencephalography (EEG) responses of three
      distinct groups of individuals to scopolamine: 1) a group of Alzheimer Dementia (AD)
      patients, 2) a group of individuals suffering from Mild Cognitive Impairment (MCI) and 3) a
      group of controls. The main purpose of this comparison is to discover ways to use these
      responses to distinguish between the group of AD patients and controls in order to develop a
      diagnostic tool for AD. The purpose of including the MCI group is to investigate whether this
      diagnostic tool can predict which member of the MCI group will develop AD later in life.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">October 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in EEG as a result of scopolamine administration</measure>
    <time_frame>1 hr after scopolamine administration</time_frame>
    <description>The EEG is recorded before, during and after scopolamine administration in order to monitor the effects scopolamine has on the brain as measured by EEG.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>AD</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Scopolamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Scopolamine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Scopolamine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Scopolamine</intervention_name>
    <description>0.3 mg/mL, intravenously, once</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>MCI</arm_group_label>
    <arm_group_label>AD</arm_group_label>
    <other_name>Scopolamine hydrobromide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy subjects:

          -  Between 60-80 years of age.

          -  Volunteers will have to be in good general health as determined by standard physical
             examination.

          -  Normal Electrocardiograph (ECG)

        MCI subjects:

          -  Diagnosed with MCI at the Memory Clinic at the Landspitali University Hospital using F
             06,7 according to International Classification of Diseases (ICD) - 10.

          -  Between 60-80 years of age.

          -  Subjects need to score between 2 and 3 on the Global Deterioration Scale (GDS).

          -  Normal ECG

        Alzheimer's patients:

          -  Diagnosed with AD according to ICD - 10 in Follow up at the Memory Clinic at the
             Landspitali University Hospital.

          -  Between 60-80 years of age.

          -  Subjects need to score between 3-5 on the GDS.

          -  Normal ECG

          -  Treated with Reminyl® for the Alzheimer disease.

        Exclusion Criteria:

          -  Smoking or any other use of tobacco.

          -  Taking neuroleptics or benzodiazepines (allowed to take oxazepam ad vesp).

          -  Neurological-, cardiovascular-, gastrointestinal- or genitourinary disorders of
             medical importance.

          -  Glaucoma or history of possibly raised intraocular pressure.

          -  Impaired liver- or kidney function.

          -  Hypersensitivity to Scopolamine or any component in the formulation.

          -  Any indication of drug, alcohol or medicine abuse.

          -  Participation in another investigational study at the same time.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jón Snædal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Landspitali University Hospital</affiliation>
  </overall_official>
  <reference>
    <citation>Gudmundsson S, Runarsson TP, Sigurdsson S, Eiriksdottir G, Johnsen K. Reliability of quantitative EEG features. Clin Neurophysiol. 2007 Oct;118(10):2162-71. Epub 2007 Aug 31.</citation>
    <PMID>17765604</PMID>
  </reference>
  <results_reference>
    <citation>Snaedal J, Johannesson GH, Gudmundsson TE, Gudmundsson S, Pajdak TH, Johnsen K. The use of EEG in Alzheimer's disease, with and without scopolamine - a pilot study. Clin Neurophysiol. 2010 Jun;121(6):836-41. doi: 10.1016/j.clinph.2010.01.008. Epub 2010 Feb 12.</citation>
    <PMID>20153691</PMID>
  </results_reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2014</study_first_submitted>
  <study_first_submitted_qc>October 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2014</study_first_posted>
  <last_update_submitted>October 22, 2014</last_update_submitted>
  <last_update_submitted_qc>October 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Scopolamine, AD, EEG, MCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scopolamine Hydrobromide</mesh_term>
    <mesh_term>Butylscopolammonium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

